A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease risk in IgA nephropathy patients

Abstract

Background and objective:

The association between angiotensin-converting enzyme (ACE) insertion/deletion (I/D) gene polymorphism and end-stage renal disease (ESRD) risk in IgA nephropathy (IgAN) patients is still controversial. A meta-analysis was performed to evaluate the association between ACE I/D gene polymorphism and ESRD susceptibility in IgAN patients.

Method:

A predefined literature search and selection of eligible relevant studies were performed to collect data from electronic databases.

Results:

Thirteen articles were identified for the analysis of the association between ACE I/D gene polymorphism and ESRD risk in IgAN patients. D allele and DD genotype were associated with ESRD susceptibility in IgAN patients for overall populations (p=0.01 and 0.003, respectively). In Asians, there was a markedly positive association between DD genotype and ESRD susceptibility (p=0.03). Furthermore, D allele and DD genotype were associated with ESRD susceptibility in Caucasians (p=0.02 and 0.03, respectively). However, II genotype might not play a protective role against ESRD onset for overall populations, Asians and Caucasians.

Conclusion:

DD homozygote is a significant genetic molecular marker for the onset of ESRD in IgAN patients.

Keywords

End-stage renal disease angiotensin-converting enzyme insertion/deletion gene polymorphism IgA nephropathy meta-analysis

Get full access to this article

View all access options for this article.

References

Rosselli

Thacker

Karpinski

. Treatment of IgA nephropathy: An update. Ann Pharmacother 2011; 45: 1284–1296.

Marson

de Figueiredo

Tanus-Santos

. Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: A potential pharmacological target. Basic Clin Pharmacol Toxicol 2012; 110: 409–415. DOI: 10.1111/j.1742-7843.2012.00863.x. Epub 2 March 2012.

Trabulus

Guven

Altiparmak

. DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease. Mol Biol Rep 2012; 39: 6995–7001.

Cheng

Zhou

Zhu

. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese. Nephrol Dial Transplant 2011; 26: 2544–2549.

Gorgi

Hbibi

Sfar

. Role of genetic polymorphisms in factor H and MBL genes in Tunisian patients with immunoglobulin A nephropathy. Int J Nephrol Renovasc Dis 2010; 3: 27–32.

Watanabe

Inoue

Okada

. Impact of selectin gene polymorphisms on rapid progression to end-stage renal disease in patients with IgA nephropathy. Intern Med 2006; 45: 947–951.

Berthoux

Mariat

. CC-chemokine receptor five gene polymorphism in primary IgA nephropathy: The 32 bp deletion allele is associated with late progression to end-stage renal failure with dialysis. Kidney Int 2006; 69: 565–572.

Tronvik

Stovner

Bovim

. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 2008; 8: 4.

Yaren

Oztop

Turgut

. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Exp Biol Med (Maywood) 2008; 233: 32–37.

10.

Bonnet

Patel

Laville

. Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. Diabetes Care 2008; 31: 789–794.

11.

Begg

Mazumdar

. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.

12.

Egger

Davey

Schneider

. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

13.

Huang

Lin

. Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy. Chin Med J (Engl) 2010; 123: 3238–3242.

14.

Lau

Woo

Choong

. ACE gene polymorphism and disease progression of IgA nephropathy in Asians in Singapore. Nephron 2002; 91: 499–503.

15.

Lau

Woo

Choong

. Renin-angiotensin system gene polymorphisms: Its impact on IgAN and its progression to end-stage renal failure among Chinese in Singapore. Nephron Physiol 2004; 97: 1–8.

16.

Ong-Ajyooth

Limmongkon

. The renin-angiotensin system gene polymorphisms and clinicopathological correlations in IgA nephropathy. J Med Assoc Thai 1999; 82: 681–689.

17.

Suzuki

Kobayashi

. Insertion/deletion polymorphism in ACE gene is not associated with renal progression in Japanese patients with IgA nephropathy. Am J Kidney Dis 2000; 35: 896–903.

18.

Woo

Chan

Choong

. High dose Losartan and ACE gene polymorphism in IgA nephritis. Genomic Med 2008; 2: 83–91.

19.

Woo

Lau

Chan

. ACE gene sequence and nucleotide variants in IgA nephropathy. Singapore Med J 2011; 52: 824–834.

20.

Shao

. Investigation on the association of angiotensin-converting enzyme gene polymorphism with IgA nephropathy risk. Chinese Journal of Integrated Traditional and Western Nephrology 2001; 2: 95–96.

21.

Yoshida

Mitarai

Kawamura

. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96: 2162–2169.

22.

Zheng

Zhang

. Relationship between angiotensin-converting enzyme insertion/deletion gene polymorphism and IgA nephropathy risk. Chinese Journal of Nephrology 1999; 15: 379–380.

23.

Woo

Lau

Zhao

. Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis. Cell Mol Immunol 2007; 4: 227–232.

24.

Schmidt

Stier

Hartung

. No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 1995; 26: 727–731.

25.

Hunley

Julian

Phillips

. Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996; 49: 571–577.

26.

Zhou

Qin

. A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and Henoch-Schönlein purpura nephritis risk in Asian children. Clin Exp Rheumatol 2012; 30: 315–316.

27.

Chen

Zhang

. A meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy. Nephrology (Carlton) 2012; 17: 480–487. DOI: 10.1111/j.1440-1797.2012.01592.x.

28.

Zhou

Qin

. Association of angiotensin converting enzyme insertion/deletion gene polymorphism with idiopathic nephrotic syndrome susceptibility in children: A meta-analysis. J Renin Angiotensin Aldosterone Syst 2011; 12: 601–610.

29.

Zhou

Qin

. Insertion/deletion (I/D) polymorphism of angiotensin-converting enzyme gene in steroid-resistant nephrotic syndrome for children: A genetic association study and meta-analysis. Ren Fail 2011; 33: 741–748.

30.

Zhou

Qin

. The association between angiotensin-converting enzyme insertion/deletion gene variant and risk of focal segmental glomerulosclerosis: A systematic review and meta-analysis. J Renin Angiotensin Aldosterone Syst 2011; 12: 624–633.

31.

Wiwanitkit

. Angiotensin-converting enzyme gene polymorphism is correlated to the progression of disease in patients with IgA nephropathy: A meta-analysis. Ren Fail 2006; 28: 697–699.

32.

Pereira

Nunes

Rudnicki

. Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: A meta-analysis. Nephrol Dial Transplant 2006; 21: 3155–3163.

33.

Brenner

Cooper

de Zeeuw

. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

34.

Lewis

Hunsicker

Clarke

. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

35.

Hou

Zhang

. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131–140.

36.

Lee

Kim

Lee

. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): A 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther 2012; 34: 552–568.

37.

Szeto

. Mineralocorticoid receptor antagonist for renal protection. Ren Fail 2012; 34: 810–817.